What is DFA working on now?
DFAs first project is a rapid, low-cost, point-of-care diagnostic device used to monitor liver function which is critical in the developing world for monitoring the adverse side effects of the powerful drugs used to treat HIV/AIDS and TB, and for managing the treatment of viral hepatitis. From a single drop of whole blood, DFAs device will allow the semi-quantitative determination of two key liver enzymes that are routinely used to measure liver toxicity among patients receiving antiretroviral medications. The test will determine whether blood levels of these two enzymes are baseline/normal, greater than 2x baseline/normal, and greater than 5x baseline/normal, important ranges for clinical decisions.
